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The most significant finding in this research period has been that making breast cancer cells folate deficient is difficult to do without killing the cells. It is much easier to target folate and one carbon metabolism in different ways such as inhibiting key enzymes with either miRNA or drugs. This is the rationale for why we have switched to making tetracycline inducible stably transduced cell lines that express miRNA against either dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR), s-adensoylhomocysteinase (AHCY) or DNA methyltransferase 1 (DNMT1). We have succeeded in expressing constructs containing miRNA for DHFR and AHCY in both MCF7 and MDA-MB-231 cells. The next steps involve selecting clones with non-leaky tetracycline repressor protein systems so that we can create the final tetracycline inducible, stably transduced cell lines. Once this has been accomplished we will begin to characterize the changes that occur to breast cancer cell growth and function when inhibition of either DHFR, AHCY, MTHFR or DNMT1 is induced. and DNA methyltransferase 1 (DNMT1) by miRNA will decrease breast cancer cell growth, modulate cell migration, and decrease the ability of the cell to survive anoikis by increasing expression of hypermethylated genes including transcription factors.
Body:
Original Tasks To characterize the effects on global and gene specific methylation and gene expression in human breast carcinoma (MCF7, MDA-MB231) and mouse mammary tumor cells (Met-1, DB-7) of the following: Once the tetracycline inducible stably transduced cell lines are made, we will perform the assays outlined in Table 1 to assess changes in breast cancer cell function and phenotype. 
Reportable Outcomes:
Abstract published and poster presentation at the Era of Hope conference 2011.
Conclusion:
Several changes have been made to the original research plan. Mainly the development of tetracycline inducible stably transduced MCF7 and MDA-MB-231 cells expressing miRNA against one of the following enzymes: dihydrofolate reductase, methylenetetrahydrofolate reductase, DNA methyltransferase 1 and Sadenosylhomocysteinase. We decided to perturb one carbon metabolism using this approach because the original approach of making cells folate deficient proved too difficult to do without killing the cells. We are focusing on making the stably cell lines from two parent cell lines of human origin. If time and funding permit we will repeat the process in the mouse cell lines listed in the original research plan (DB7 and Met 1). In 1998 the U.S. government implemented mandatory fortification of cereal grain products with folic acid to decrease the incidence of neural tube defects (NTDs). While this action was successful in lowering NTD incidence, recent epidemiological studies are highlighting a possible association between excess folic acid and cancer incidence. Current research on the effects of excess folic acid on breast cancer initiation and progression are inconclusive.
DNA methylation is a form of epigenetic regulation that results in chromatin remodeling and ultimately gene silencing. It is essential for cellular differentiation and function. Aberrant DNA methylation is a characteristic of cancer cells, including mammary tumors. The B vitamin folate is required for the synthesis of purines, thymidine, and S-adenosylmethionine (SAM), the methyl donor for DNA methylation. DNA methyltransferase 1 maintains methylation patterns and catalyzes the transfer of the methyl group from SAM to a cytosine residue.
Our objective is to understand the relationships between folate, one-carbon metabolism, DNA methylation, and gene expression within the context of breast cancer. We hypothesize that modulation of folic acid levels or inhibition of key enzymes in one-carbon metabolism (dihydrofolate reductase Working with two parent breast cancer cell lines, MCF7 and MDA MB 231, we have developed tetracycline-inducible, stably transfected cell lines that have one of the enzymes listed (DHFR, MTHFR, DNMT1, or AHCY) knocked down. We will compare the effects of knocking down enzyme expression in this way to the effects of treating breast cancer cells with methotrexate or excess folic acid. We will measure changes in cell growth, migration, survival of anoikis, global and gene-specific DNA methylation changes, as well as one-carbon metabolite levels.
